The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.

Idera Pharmaceuticals, Inc. (IDRA) (the Company) today is announcing final topline data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist. ILLUMINATE-204 is a multi-center, two-arm phase 1/2 trial in patients with anti-PD-1 refractory advanced melanoma. The phase 1 portion of the trial tested the safety and efficacy of increasing doses of tilsotolimod in combination with either Yervoy®* (ipilimumab) or Keytruda®± (pembrolizumab).

Idera Pharmaceuticals, Inc. (IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No. 10,10,463,686 entitled “Immune Modulation With TLR9 Agonists For Cancer Treatment,” which includes the Company’s investigational therapy tilsotolimod (IMO-2125). Idera also continues to focus on the acquisition, development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Idera Pharmaceuticals, Inc. (“Idera”) (IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, to be held April 27-28, 2020, as part of a “Clinical Trial Poster Session.” ILLUMINATE-206 is an ongoing phase 2, open-label, multicohort, multicenter study to test the safety and efficacy of intratumoral tilsotolimod in combination with Yervoy®* (ipilimumab) and Opdivo® (nivolumab) for the treatment of solid tumors. ILLUMINATE-101 was a phase 1b trial of intratumoral tilsotolimod monotherapy in patients with refractory solid tumors, which was completed in December 2019.

EXTON, Pa., April 30, 2020 -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has rebounded strongly over the last week, with the share price soaring 34...

Idera Pharmaceuticals, Inc. (IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional investor providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to which Idera has sold shares of Series B1 convertible preferred stock and warrants to purchase common stock for aggregate gross proceeds of $3.9 million. In connection with the agreement for the private placement, the investors in the private placement will pay Idera an upfront option fee of approximately $6.2 million.

Vinnie, Vin Milano became the CEO of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2014. This analysis aims first to...

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its registrational trial of tilsotolimod in combination with ipilimumab in patients with anti-PD-1 refractory advanced melanoma. The company expects to announce top-line overall response rate (ORR) and other preliminary data from ILLUMINATE-301 in Q1 2021. “We are making outstanding progress in moving toward our goal of delivering tilsotolimod to the market in our lead indication for anti-PD-1 refractory advanced melanoma patients,” stated Vincent Milano, Idera’s Chief Executive Officer.

Idera Pharmaceuticals, Inc. (IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9) agonist, in combination with nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody for the treatment of solid tumors. To learn more about Idera, visit www.iderapharma.com.

EXTON, Pa., April 07, 2020 -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor.

EXTON, Pa., Nov. 06, 2019 -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the.

Largest insider trades of the week Continue reading...

EXTON, Pa., March 12, 2020 -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Idera Pharmaceuticals, Inc. (IDRA), or Idera or the Company, today is providing an update on its tilsotolimod clinical development program and providing a corporate outlook for 2020. “We made tremendous progress last year with the tilsotolimod clinical development program, and we are positioned well going into this pivotal year,” stated Vincent Milano, Idera’s Chief Executive Officer.

Due to the public health impact of the coronavirus (COVID-19) pandemic and related government actions, and to support the health and well-being of our employees, stockholders, and community, the location of Idera’s Annual Meeting has been changed and will be held in a virtual meeting format only. The Annual Meeting is open to stockholders who owned shares as of March 24, 2020 (the “Record Date”), proxy holders, and any other interested party that would like to participate as a guest. Stockholders are encouraged to vote and submit proxies in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.

The deal consists of a private placement, an option fee, and an option to purchase future shares if current stockholders approve.